DXCM240927C69000
- 0.17
- -0.03-15.00%
DexCom Newsroom
Piper Sandler Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
Oppenheimer Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $115
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Analysts' Top Healthcare Picks: Dexcom (DXCM), Ascendis Pharma (ASND)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Wells Fargo Releases a Buy Rating on Dexcom (DXCM)
Dexcom's Stelo Sees Strong Market Adoption: Justifying a Buy Rating
Morgan Stanley Maintains DexCom(DXCM.US) With Hold Rating, Cuts Target Price to $75
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $89
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $80 to $120
Barclays Keeps Their Hold Rating on Dexcom (DXCM)
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
DexCom Analyst Ratings
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $100
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $130
RBC Capital Sticks to Their Buy Rating for Dexcom (DXCM)
Dexcom (DXCM) Receives a Buy From Wells Fargo